Drug Regulation

The Elixir Sulfanilamide tragedy prompted the Food, Drug, and Cosmetic Act. A sweet-tasting medication containing the toxic compound diethyl glycol caused numerous deaths. This disaster established the requirement that drug companies demonstrate product safety through toxicity studies and accurate labeling before market approval.

The Kefauver-Harris Amendments of 1962, enacted after the thalidomide disaster, mandated manufacturers to provide evidence of both drug efficacy and safety using the risk-to-benefit ratio. Animal research became mandatory before human trials. This represented a major shift from earlier regulations that required only safety demonstration without efficacy proof.

An IND (Investigational New Drug) application is a submission to the FDA containing data from preclinical development and animal research. Manufacturers compile results from toxicity studies and animal trials into this application before proceeding to human testing. The IND serves as the formal request to begin clinical investigation of a new drug candidate.

Animal research became mandatory following the thalidomide disaster to establish safety and efficacy before exposing humans to experimental drugs. This requirement ensures that preliminary toxicity and effectiveness data are collected in controlled laboratory settings. Animal studies now form a critical component of the regulatory pathway preceding human clinical trials.

The FDA accelerated the drug approval process by prioritizing review of medications for fatal illnesses and becoming more actively involved in drug development. These measures aimed to reduce approval timelines while maintaining safety and efficacy standards. The FDA's proactive engagement helps streamline the pathway from discovery to patient access for critical therapies.

The 1938 Food, Drug, and Cosmetic Act required only safety demonstration through toxicity studies and labeling. The 1962 Kefauver-Harris Amendments added the mandatory requirement for efficacy evidence evaluated through risk-to-benefit analysis. This evolution reflected lessons from drug disasters and established more comprehensive regulatory standards for pharmaceutical approval.

Drug regulation controls medication use through systematic safety and efficacy evaluations by regulatory bodies like the FDA. Requirements include toxicity studies, animal research, risk-to-benefit assessment, and accurate labeling. These safeguards prevent harmful substances from reaching patients and ensure that approved drugs demonstrate both safety and therapeutic effectiveness.